Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to AveroaGlobeNewsWire • 04/03/25
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025GlobeNewsWire • 03/25/25
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionBenzinga • 03/20/25
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/13/25
Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress UpdateGlobeNewsWire • 03/13/25
Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business HighlightsGlobeNewsWire • 03/06/25
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePRNewsWire • 12/18/24
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on DialysisPRNewsWire • 12/03/24
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare ConferencePRNewsWire • 11/25/24
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney DiseasePRNewsWire • 11/14/24
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/07/24